Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed May 9, 2019 · 10-Q · 39 days after period end · 0001615774-19-007324
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Net Income | -$7.25M | -$4.75M | -$1.55M | -$2.03M |
| EPS Diluted | -$0.15 | -$0.11 | -$0.04 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end
